数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Oropharyngeal carcinoma (OPHC) belongs to the head and neck carcinoma (HNC) superfamily of malignant entities.
方法
There is an increasing interest in developing and applying novel mTOR inhibitors in subsets of patients with the malignancy that demonstrate specific genetic signatures.
核心结论
Concerning the molecular substrate of OPHSCCs, imbalances in signal transduction pathways are implicated in their onset and progression.；Among them, the phosphatidylinositol 3-kinase (PI3K)/tumor suppressor phosphatase and tensin homologue deleted on chromosome ten (PTEN)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway deregulation critically affects the clinico-pathological features and biological behavior of the corresponding malignancies.；Especially, the mTOR oncogene (gene locus: 1p36.2) overactivation, due to point mutations and gene amplification, is a relatively frequent genetic event in OPHSCCs.；For this reason, the molecule is a target for specific oncological therapeutic regimens. ‖ 结论：In the current review, we focused on the mTOR gene and protein characteristics, their deregulation mechanisms in OPHSCCs and the conventional and novel agents that target and disrupt mTOR oncogenic activity in them.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★★☆☆ 营养感知与自噬轴决定"干预窗口 + 剂量方案"，是组合疗法的时间锚。
原文题录
- 英文标题：mTOR Inhibition Strategies in Oropharyngeal Carcinoma.
- 期刊与标识：Anticancer Res · PMID 42946450 · DOI 10.21873/anticanres.18430**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。